Sidney Kimmel Cancer Center LAPS Institutional Collaboration

悉尼金梅尔癌症中心 LAPS 机构合作

• 批准号: 10115650
• 负责人: Steven Cohen
• 金额: $ 39.85万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10115650
• 关键词: Address; Advanced Malignant Neoplasm; American College of Radiology Imaging Network; Basic Science; Cancer Biology; Cancer Center; Catchment Area; Characteristics; Cities; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical assessments; Collaborations; Communities; Complement; County; Delaware; Discipline; Eastern Cooperative Oncology Group; Education; Faculty; Fostering; Funding Opportunities; Goals; Health; Health system; Hospitals; Incidence; Industry; Infrastructure; Institution; Knowledge; Laboratories; Laboratory Research; Lead; Leadership; Malignant Neoplasms; NCI Center for Cancer Research; NCI-Designated Cancer Center; National Clinical Trials Network; New Jersey; Oncology; Oncology Group; Outreach Research; Participant; Patients; Pennsylvania; Philadelphia; Population Heterogeneity; Population Research; Positioning Attribute; Process; Protocols documentation; Radiation Therapy Oncology Group; Research; Research Personnel; Research Priority; Role; Shapes; Site; System; Technology; Time; Translational Research; Underserved Population; United States National Institutes of Health; base; bench to bedside; cancer care; career development; community engagement; data quality; design; health equity; innovation; leadership development; member; mortality; outreach; performance site; population based; programs; rare cancer; research study; socioeconomics; symptom management

ABSTRACT The overarching goal of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. SKCC is a NCI-designated cancer center nucleated at the Jefferson Health-Center City campus and enriched by fully integrated research components at Jefferson Health-Abington and Jefferson Health-Aria. Building on these strengths, SKCC focuses on addressing catchment area needs through nurturing transdisciplinary research, expanding innovative research capabilities, extending outreach and clinical research into the community, and enhancing the pace of bench-to-bedside discovery. The Jefferson Health system has expanded over the last 3 years and now includes a system of 12 Hospitals treating more than 8,000 new cancer cases annually. The SKCC catchment area includes Philadelphia, Montgomery, and Delaware counties in Pennsylvania, and Camden County in New Jersey. Philadelphia's highly diverse population, with numerous socioeconomic, racial, and health challenges characteristic of major northeastern cities, shapes SKCC research priorities and outreach. At any given time, hundreds of research studies are underway at the cancer center, ranging from basic laboratory research to clinical assessments of new treatments to meet the needs of this diverse population. Many of these studies are collaborative, involving other cancer centers or other partners in industry and the community. The overall objective and goal of this proposal is to enable SKCC to participate as a Lead Academic Participating Site (LAPS) in the NCI National Clinical Trial Network (NCTN) Clinical Research Program. This goal will be achieved through providing scientific leadership for development and execution of NCTN trials complemented by an integrated and collaborative research program. The SKCC has an established and well supported infrastructure to nurture discoveries and processes that advance our fundamental knowledge of cancer biology and implementing them into the community. As an NCI-designated Cancer Center, SKCC addresses the cancer needs of a diverse population through integration of laboratory and population-based clinical research, engagement of the community in relevant research to identified challenges, outreach, and education regarding clinical trials. We propose the following specific aims in this LAPS application: Specific Aim 1: Deliver and enhance access to the most advanced cancer care through participation and dissemination of NCTN initiatives including trials for rare tumors across the SKCC. Specific Aim 2: Promote and support the scientific leadership within the NCTN. Specific Aim 3: To foster junior faculty investigators' career development through NCTN participation in both NCTN/NCI committee engagement and as key contributors to conceptual protocol designs.

摘要 西德尼·基梅尔癌症中心(SKCC)的首要目标是利用研究专业知识来减少 大费城及其他地区癌症的总发病率、负担和死亡率。SKCC的目标是 通过基础、临床、 和人口研究学科。SKCC是美国国家癌症研究所指定的癌症中心，位于杰斐逊 健康中心城市园区，并得到杰斐逊健康-阿宾顿分校全面整合的研究组成部分的丰富 和杰斐逊健康-艾瑞亚。在这些优势的基础上，SKCC专注于解决集水区的需求 通过培育跨学科研究，扩大创新研究能力，扩大外延 和临床研究进入社区，并加快从病床到床边发现的步伐。这个 杰斐逊医疗系统在过去3年中得到了扩展，现在包括12家医院 每年治疗8000多例新的癌症病例。SKCC集水区包括费城， 宾夕法尼亚州的蒙哥马利县和特拉华县，以及新泽西州的卡姆登县。费城的 人口高度多样化，面临着许多社会经济、种族和健康方面的挑战 东北城市，塑造了SKCC的研究重点和拓展范围。在任何给定的时间，数百项研究 癌症中心正在进行研究，范围从基础实验室研究到临床评估 新的治疗方法，以满足这一多样化人口的需求。其中许多研究都是合作的，涉及 其他癌症中心或行业和社区的其他合作伙伴。这项工作的总体目标和目标 建议使SKCC能够作为NCI National的领先学术参与站点(LAPS)参与 临床试验网络(NCTN)临床研究计划。这一目标将通过提供 科学领导NCTN试验的开发和执行，并辅之以综合和 合作研究计划。SKCC有一个成熟的、得到良好支持的基础设施需要培育 促进我们癌症生物学基础知识并付诸实施的发现和过程 融入社区。作为NCI指定的癌症中心，SKCC满足了不同癌症患者的需求 通过整合实验室和以人群为基础的临床研究，参与 社区参与相关研究，以确定与临床试验有关的挑战、推广和教育。我们 在此LAPS应用程序中提出以下具体目标：具体目标1：交付和增强访问 通过参与和传播NCTN倡议提供最先进的癌症护理，包括试验 整个SKCC都有罕见的肿瘤。具体目标2：促进和支持联合国系统内的科学领导 NCTN。具体目标3：通过参与NCTN促进初级教研员的职业发展 在NCTN/NCI委员会参与和作为概念性协议设计的关键贡献者。